117 related articles for article (PubMed ID: 24081245)
1. Treatment switching in idiopathic pulmonary fibrosis: from triple therapy to enrollment into a clinical investigational drug trial.
Valenzuela C; Ancochea J
Sarcoidosis Vasc Diffuse Lung Dis; 2013 Sep; 30 Suppl 1():44-7. PubMed ID: 24081245
[TBL] [Abstract][Full Text] [Related]
2. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial.
Behr J; Bendstrup E; Crestani B; Günther A; Olschewski H; Sköld CM; Wells A; Wuyts W; Koschel D; Kreuter M; Wallaert B; Lin CY; Beck J; Albera C
Lancet Respir Med; 2016 Jun; 4(6):445-53. PubMed ID: 27161257
[TBL] [Abstract][Full Text] [Related]
3. Recent evidence for pharmacological treatment of idiopathic pulmonary fibrosis.
Covvey JR; Mancl EE
Ann Pharmacother; 2014 Dec; 48(12):1611-9. PubMed ID: 25202034
[TBL] [Abstract][Full Text] [Related]
4. Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis.
Rogliani P; Calzetta L; Cavalli F; Matera MG; Cazzola M
Pulm Pharmacol Ther; 2016 Oct; 40():95-103. PubMed ID: 27481628
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of combined therapy with pirfenidone and inhaled N-acetylcysteine for advanced idiopathic pulmonary fibrosis: a case-control study.
Sakamoto S; Muramatsu Y; Satoh K; Ishida F; Kikuchi N; Sano G; Sugino K; Isobe K; Takai Y; Homma S
Respirology; 2015 Apr; 20(3):445-52. PubMed ID: 25639750
[TBL] [Abstract][Full Text] [Related]
6. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.
; Raghu G; Anstrom KJ; King TE; Lasky JA; Martinez FJ
N Engl J Med; 2012 May; 366(21):1968-77. PubMed ID: 22607134
[TBL] [Abstract][Full Text] [Related]
7. Lung function in idiopathic pulmonary fibrosis--extended analyses of the IFIGENIA trial.
Behr J; Demedts M; Buhl R; Costabel U; Dekhuijzen RP; Jansen HM; MacNee W; Thomeer M; Wallaert B; Laurent F; Nicholson AG; Verbeken EK; Verschakelen J; Flower CD; Petruzzelli S; De Vuyst P; van den Bosch JM; Rodriguez-Becerra E; Lankhorst I; Sardina M; Boissard G;
Respir Res; 2009 Oct; 10(1):101. PubMed ID: 19860915
[TBL] [Abstract][Full Text] [Related]
8. Treatment of idiopathic pulmonary fibrosis: a network meta-analysis.
Rochwerg B; Neupane B; Zhang Y; Garcia CC; Raghu G; Richeldi L; Brozek J; Beyene J; Schünemann H
BMC Med; 2016 Feb; 14():18. PubMed ID: 26843176
[TBL] [Abstract][Full Text] [Related]
9. Recommendations on treatment for IPF.
Behr J; Richeldi L
Respir Res; 2013; 14 Suppl 1(Suppl 1):S6. PubMed ID: 23734936
[TBL] [Abstract][Full Text] [Related]
10. Where do we stand with IPF treatment?
Albera C; Ferrero C; Rindone E; Zanotto S; Rizza E
Respir Res; 2013; 14 Suppl 1(Suppl 1):S7. PubMed ID: 23734956
[TBL] [Abstract][Full Text] [Related]
11. Effects and mechanisms of pirfenidone, prednisone and acetylcysteine on pulmonary fibrosis in rat idiopathic pulmonary fibrosis models.
Yu W; Guo F; Song X
Pharm Biol; 2017 Dec; 55(1):450-455. PubMed ID: 27937011
[TBL] [Abstract][Full Text] [Related]
12. Design and rationale for the prospective treatment efficacy in IPF using genotype for NAC selection (PRECISIONS) clinical trial.
Podolanczuk AJ; Kim JS; Cooper CB; Lasky JA; Murray S; Oldham JM; Raghu G; Flaherty KR; Spino C; Noth I; Martinez FJ;
BMC Pulm Med; 2022 Dec; 22(1):475. PubMed ID: 36514019
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Longevity in Patients with Idiopathic Pulmonary Fibrosis Using Pirfenidone Versus Triple Therapy with Prednisolone, Azathioprine, and Acetylcysteine.
Asl MS; Motakef Z; Behgam N; Attaran S; Mirsadraee M
Tanaffos; 2023 Jan; 22(1):129-135. PubMed ID: 37920315
[TBL] [Abstract][Full Text] [Related]
14. Role of Pirfenidone in Idiopathic Pulmonary Fibrosis - A Longitudinal Cohort Study.
Suraj KP; Kumar NK; Jyothi E; Narayan KV; Biju G
J Assoc Physicians India; 2016 May; 64(5):36-41. PubMed ID: 27735147
[TBL] [Abstract][Full Text] [Related]
15. Long-term management of IPF with pirfenidone - a clinical case study with 5 years follow-up.
Richeldi L; Sgalla G; Cerri S
Sarcoidosis Vasc Diffuse Lung Dis; 2013 Sep; 30 Suppl 1():52-62. PubMed ID: 24081247
[TBL] [Abstract][Full Text] [Related]
16. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.
; Martinez FJ; de Andrade JA; Anstrom KJ; King TE; Raghu G
N Engl J Med; 2014 May; 370(22):2093-101. PubMed ID: 24836309
[TBL] [Abstract][Full Text] [Related]
17. Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis.
Ley B; Swigris J; Day BM; Stauffer JL; Raimundo K; Chou W; Collard HR
Am J Respir Crit Care Med; 2017 Sep; 196(6):756-761. PubMed ID: 28471697
[TBL] [Abstract][Full Text] [Related]
18. A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK.
Rinciog C; Watkins M; Chang S; Maher TM; LeReun C; Esser D; Diamantopoulos A
Pharmacoeconomics; 2017 Apr; 35(4):479-491. PubMed ID: 28039616
[TBL] [Abstract][Full Text] [Related]
19. TOLLIP, MUC5B, and the Response to N-Acetylcysteine among Individuals with Idiopathic Pulmonary Fibrosis.
Oldham JM; Ma SF; Martinez FJ; Anstrom KJ; Raghu G; Schwartz DA; Valenzi E; Witt L; Lee C; Vij R; Huang Y; Strek ME; Noth I;
Am J Respir Crit Care Med; 2015 Dec; 192(12):1475-82. PubMed ID: 26331942
[TBL] [Abstract][Full Text] [Related]
20. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial.
Raghu G; Depaso WJ; Cain K; Hammar SP; Wetzel CE; Dreis DF; Hutchinson J; Pardee NE; Winterbauer RH
Am Rev Respir Dis; 1991 Aug; 144(2):291-6. PubMed ID: 1859050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
